FINWIRES · TerminalLIVE
FINWIRES

加拿大豐業銀行稱,加拿大春季經濟聲明將保持成長勢頭

-- 加拿大豐業銀行表示,下週二,加拿大人將首次了解總理馬克卡尼政府在新財政框架下推行的萬億加元計畫的進展。 該銀行指出,2026年春季經濟報告將在全球高度不確定的背景下發布,反而凸顯了加拿大雄心勃勃的投資主導型策略的必要性。 豐業銀行表示,儘管短期經濟活動依然疲軟,但隨著風險的消散,經濟復甦動能應該會增強。由於通膨風險目前暫時使加拿大央行無暇顧及,短期壓力更多地轉移到了財政政策上,如果下行風險成為現實,保持政策選擇權或許是更穩健的選擇。 該銀行指出,儘管面臨許多不利因素,但更強勁的名義成長前景可能意味著此次更新將帶來更大的財政空間。這可能為增加支出打開大門,不過豐業銀行預計,這些支出仍將在先前設定的赤字範圍內進行。 在這種情況下,負債比率可能會顯著改善,反映出歷史國內生產毛額(GDP)的大幅修正。 此次更新將在高度波動的市場環境下發布。該銀行補充道,即使財政政策運作得當,但最終結果可能不會有實質變化,短期內也不太可能對市場產生影響。 更重要的是,要觀察投資議程是否正在取得進展,因為一些投資者可能仍會對執行情況和地緣政治風險保持謹慎。 總而言之,此次更新的目的可能是保持成長動能並提高執行效率,同時為2026年預算案中更大膽的措施奠定基礎。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA